1. Lötvall J, Akdis CA, Bacharier LB, Bjermer L, Casale TB, Custovic A, et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol. 2011; 127:355–360.
2. Nelson RP Jr, DiNicolo R, Fernández-Caldas E, Seleznick MJ, Lockey RF, Good RA. Allergen-specific IgE levels and mite allergen exposure in children with acute asthma first seen in an emergency department and in nonasthmatic control subjects. J Allergy Clin Immunol. 1996; 98:258–263.
3. Wong GW, Li ST, Hui DS, Fok TF, Zhong NS, Chen YZ, et al. Individual allergens as risk factors for asthma and bronchial hyperresponsiveness in Chinese children. Eur Respir J. 2002; 19:288–293.
4. Obase Y, Shimoda T, Mitsuta K, Matsuo N, Matsuse H, Kohno S. Sensitivity to the house dust mite and airway hyperresponsiveness in a young adult population. Ann Allergy Asthma Immunol. 1999; 83:305–310.
5. Kowal K, Møller HJ, Dubuske LM, Moestrup SK, Bodzenta-Lukaszyk A. Differential expression of monocyte CD163 in single- and dual-asthmatic responders during allergen-induced bronchoconstriction. Clin Exp Allergy. 2006; 36:1584–1591.
6. Kowal K, Bodzenta-Lukaszyk A, Zukowski S. Exhaled nitric oxide in evaluation of young adults with chronic cough. J Asthma. 2009; 46:692–698.
9. Jolly PS, Rosenfeldt HM, Milstien S, Spiegel S. The roles of sphingosine-1-phosphate in asthma. Mol Immunol. 2002; 38:1239–1245.
10. Lai WQ, Wong WS, Leung BP. Sphingosine kinase and sphingosine 1-phosphate in asthma. Biosci Rep. 2011; 31:145–150.
12. Ono JG, Worgall TS, Worgall S. Airway reactivity and sphingolipids-implications for childhood asthma. Mol Cell Pediatr. 2015; 2:13.
13. Yang Y, Uhlig S. The role of sphingolipids in respiratory disease. Ther Adv Respir Dis. 2011; 5:325–344.
![crossref](/image/icon/bnr_ref_cross.gif)
15. Roviezzo F, Sorrentino R, Bertolino A, De Gruttola L, Terlizzi M, Pinto A, et al. S1P-induced airway smooth muscle hyperresponsiveness and lung inflammation
in vivo: molecular and cellular mechanisms. Br J Pharmacol. 2015; 172:1882–1893.
17. Price MM, Oskeritzian CA, Falanga YT, Harikumar KB, Allegood JC, Alvarez SE, et al. A specific sphingosine kinase 1 inhibitor attenuates airway hyperresponsiveness and inflammation in a mast cell-dependent murine model of allergic asthma. J Allergy Clin Immunol. 2013; 131:501–511.e1.
18. Karmouty-Quintana H, Siddiqui S, Hassan M, Tsuchiya K, Risse PA, Xicota-Vila L, et al. Treatment with a sphingosine-1-phosphate analog inhibits airway remodeling following repeated allergen exposure. Am J Physiol Lung Cell Mol Physiol. 2012; 302:L736–45.
![crossref](/image/icon/bnr_ref_cross.gif)
19. Ammit AJ, Hastie AT, Edsall LC, Hoffman RK, Amrani Y, Krymskaya VP, et al. Sphingosine 1-phosphate modulates human airway smooth muscle cell functions that promote inflammation and airway remodeling in asthma. FASEB J. 2001; 15:1212–1214.
20. Fuerst E, Foster HR, Ward JP, Corrigan CJ, Cousins DJ, Woszczek G. Sphingosine-1-phosphate induces pro-remodeling response in airway smooth muscle cells. Allergy. 2014; 69:1531–1539.
22. Kowal K, Pampuch A, Kowal-Bielecka O, DuBuske LM, Bodzenta-Łukaszyk A. Platelet activation in allergic asthma patients during allergen challenge with
Dermatophagoides pteronyssinus
. Clin Exp Allergy. 2006; 36:426–432.
23. Baranowski M, Charmas M, Długołęcka B, Górski J. Exercise increases plasma levels of sphingoid base-1 phosphates in humans. Acta Physiol (Oxf). 2011; 203:373–380.
24. Knapp M, Lisowska A, Knapp P, Baranowski M. Dose-dependent effect of aspirin on the level of sphingolipids in human blood. Adv Med Sci. 2013; 58:274–281.
26. Chiba Y, Takeuchi H, Sakai H, Misawa M. SKI-II, an inhibitor of sphingosine kinase, ameliorates antigen-induced bronchial smooth muscle hyperresponsiveness, but not airway inflammation, in mice. J Pharmacol Sci. 2010; 114:304–310.
27. Sawicka E, Zuany-Amorim C, Manlius C, Trifilieff A, Brinkmann V, Kemeny DM, et al. Inhibition of Th1- and Th2-mediated airway inflammation by the sphingosine 1-phosphate receptor agonist FTY720. J Immunol. 2003; 171:6206–6214.
28. Rumzhum NN, Rahman MM, Oliver BG, Ammit AJ. Effect of sphingosine 1-phosphate on cyclo-oxygenase-2 expression, prostaglandin E2 secretion, and β2-adrenergic receptor desensitization. Am J Respir Cell Mol Biol. 2016; 54:128–135.
29. Roviezzo F, Del Galdo F, Abbate G, Bucci M, D'Agostino B, Antunes E, et al. Human eosinophil chemotaxis and selective
in vivo recruitment by sphingosine 1-phosphate. Proc Natl Acad Sci U S A. 2004; 101:11170–11175.
31. Olivera A, Urtz N, Mizugishi K, Yamashita Y, Gilfillan AM, Furumoto Y, et al. IgE-dependent activation of sphingosine kinases 1 and 2 and secretion of sphingosine 1-phosphate requires Fyn kinase and contributes to mast cell responses. J Biol Chem. 2006; 281:2515–2525.
32. Roviezzo F, Sorrentino R, Iacono VM, Brancaleone V, Terlizzi M, Riemma MA, et al. Disodium cromoglycate inhibits asthma-like features induced by sphingosine-1-phosphate. Pharmacol Res. 2016; 113:626–635.
33. Moffatt MF, Kabesch M, Liang L, Dixon AL, Strachan D, Heath S, et al. Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma. Nature. 2007; 448:470–473.
34. Levy BD. Sphingolipids and susceptibility to asthma. N Engl J Med. 2013; 369:976–978.
35. Miller M, Rosenthal P, Beppu A, Gordillo R, Broide DH. Oroscomucoid like protein 3 (ORMDL3) transgenic mice have reduced levels of sphingolipids including sphingosine-1-phosphate and ceramide. J Allergy Clin Immunol. 2017; 139:1373–1376.e4.
37. Ferrando M, Bagnasco D, Varricchi G, Bernardi S, Bragantini A, Passalacqua G, et al. Personalized medicine in allergy. Allergy Asthma Immunol Res. 2017; 9:15–24.
38. Braido F, Tiotiu A, Kowal K, Mihaicuta S, Novakova P, Oguzulgen IK. Phenotypes/endotypes-driven treatment in asthma. Curr Opin Allergy Clin Immunol. 2018; 18:184–189.